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Mortalin/GRP75 is a ubiquitous mitochondrial chaperone related to the cytosolic heat shock protein 70 (HSP70). It protects
cells from senescence and apoptosis and is overexpressed in cancer cells. Cell resistance to complement-dependent cytotoxic-
ity depends on mortalin and during complement attack mortalin is released from cells. Our goal was to determine whether
cancer patients have circulating mortalin in blood. The significance of mortalin in blood to survival prospects of colorectal
cancer patients was evaluated. Occurrence of extracellular soluble HSP70 (sHSP70) is documented. We developed a sensitive
ELISA for mortalin. The association between mortalin level and survival was subjected to the Cox proportional hazards analy-
sis (univariate and multivariate analyses). Mortalin concentration in serum of colorectal cancer patients was 10–214 ng/ml.
Survival data of the patients were known from an earlier study of sHSP70 in these samples. Cox regression analysis indicated
that high mortalin (>60 ng/ml) is a risk factor for shorter survival. Serum levels of sHSP70 and mortalin in patients were inde-
pendent variables. Concurrence of high sHSP70 and mortalin was associated with rapid disease progression (HR54, 2.04–
8.45, p< 0.001). Addition of high sHSP70 and mortalin to a baseline model of age, sex and TNM stage, significantly
(p< 0.001) enhanced the risk score to 8 (3.26–20.46). This is the first demonstration of circulating mortalin in cancer
patients. Analysis of mortalin in blood, and even more so of mortalin and sHSP70, adds a high prognostic value to the TNM
stage and will identify colorectal cancer patients at high risk of poor survival.
Mortalin (mthsp70/grp75), the mitochondrial heat shock
protein 70, plays a major role in import and refolding of mi-
tochondrial proteins.1–3 Mortalin is ubiquitously and constitu-
tively expressed in all eukaryotic cells and its expression is not
heat-induced, yet may be affected following ionizing radiation
and glucose deprivation.4,5 Overexpression of mortalin protects
cells from glucose deprivation and reactive oxygen species accu-
mulation6 and from serum deprivation,7 reduced oxidative stress,
antagonized ischemic damage,8 resulted in lifespan extension of
ﬁbroblasts and promoted tumorigenesis.9 In contrast, knock
down of mortalin by RNA interference caused senescence-like
growth arrest in immortalized cells.10 Synthesized with a mito-
chondrial-targeting sequence, mortalin is mainly located in
mitochondria, yet few reports identiﬁed it in other cellular com-
partments such as the cytosol and plasma membrane.11
Several human transformed and tumor cells have been
shown to express elevated levels of mortalin.9,12 In human
colorectal adenocarcinoma, higher mortalin expression corre-
lated with poor patient survival.13 Mortalin plays a role in
the protection of cancer cells from complement-dependent
cytotoxicity.14,15 It facilitates elimination of the complement
membrane attack complex (MAC) from the cell surface by
exo-vesiculation.14 Mortalin inhibitors sensitized the cells to
complement-dependent cytotoxicity and inhibited the shed-
ding of mortalin with the MAC.15
In vitro studies showed that during complement MAC
attack, mortalin is shed from attacked cells.14,16 This was the
ﬁrst demonstration of extracellular mortalin,14 yet the release
of cytosolic HSP70 from cells is a well-known phenom-
enon.17 Extracellular HSP70 was also identiﬁed in blood
plasma of patients with colorectal cancer,18 and was found to
be a useful, stage-independent prognostic marker in colo-
rectal cancer, especially in patients without distant metastasis.
Plasma levels of HSP70 and acute phase proteins could inde-
pendently predict survival in patients with colorectal cancer
but their combined measurements gave even a higher predic-
tion value in speciﬁc subgroups of patients.19 To determine
the amount of mortalin in the plasma of the same cancer
patients, we developed a sensitive ELISA for mortalin. By
using this ELISA we identiﬁed mortalin in blood serum of
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colorectal patients. As shown here, higher serum mortalin
level correlated with faster disease progression. The hazard
index was found to be very high when levels of both mortalin
and HSP70 in serum were elevated and even higher when
combined with the TNM cancer stage.
Material and Methods
Serum samples
Serum samples of colorectal cancer patients were collected at
the outpatient oncology clinic of the 3rd Department of
Internal Medicine, Semmelweis University, Budapest, between
October 2000 and March 2005. A number of 175 consecutive
patients, diagnosed with colorectal cancer, who were willing
to give informed consent for the study, were enrolled regard-
less of tumor stage.18 Serum samples of 121 of these patients
were available for this study and the median follow-up time
was increased from 33 to 42 months. This patient cohort was
already tested for the association between sHSP70 levels and
survival18 and between acute phase proteins plus sHSP70 and
survival,19 except for four patients with no available serum
samples for the present study. In the majority of cases, the
primary tumor was removed surgically, according to relevant
international guidelines, and patients were enrolled 4–6
weeks after surgery when blood was collected for the current
study. In 16 cases, the primary tumor could not be removed
before inclusion; these patients had advanced, metastatic
tumors and were referred for primary chemotherapy. The
patients were followed during and after chemotherapy in a
protocol-based manner and health status and disease out-
come were registered. More information on the patients is
available in our earlier publications.18,19 The study received
approvals by the ethical committees of Semmelweis Univer-
sity, Budapest and Tel Aviv University, Tel Aviv. One hun-
dred sixty-three of the 175 patients were followed up until
May 2011 and their survival recorded.
Mortalin ELISA
To be able to measure serum levels of mortalin, we developed
the following capture ELISA. Wells of 96-well MaxiSorp
Nunc-Immuno plate (Thermo, Rochester, NY) were coated
overnight at 4C with 1 mg/ml mouse monoclonal antibody
directed to human mortalin (StressMarq, Victoria, Canada)
in Tris buffer (TB) (50 mM Tris Base pH 7.0, 100 mM
NaCl). The wells were blocked with bovine serum albumin
15 mg/ml (Sigma-Aldrich, Israel) in Tris-buffered saline for 1
hr at 37C and then serum samples diluted 1:3 in TB were
added to the wells for 2 h at 37C. Next, the wells were
washed with TBT (TB with 0.05% Tween-20) and treated
with a goat anti-mortalin polyclonal antibody (Santa Cruz Bio-
technology, Santa Cruz, CA) diluted in TB for 1 hr at 37C.
Finally, after a wash with TBT, peroxidase-conjugated donkey
anti-goat IgG (Jackson ImmunoResearch Laboratories, West
Grove, PA) diluted in TB was added for 1 hr at 25C. Anti-
body binding was quantiﬁed by using TMB One Component
Microwell Substrate (SouthernBiotech, Birmingham, AL) and
absorbance was read at 450 nm in a Microplate Reader (Spec-
traﬂuor plus, Tecan, Austria). Calibration of the quantity of
mortalin was included in each ELISA plate with 0–2.5 ng puri-
ﬁed recombinant mortalin (Saar et al., in preparation) mixed
with normal human serum (same dilution as the tested sam-
ples). Speciﬁcity of the anti-mortalin antibodies used was con-
ﬁrmed in Western blots showing a single protein band in
whole cell lysates (similar to the bands shown in Ref. 15). Pu-
rity of the recombinant mortalin was also conﬁrmed.15 Ab-
sorbance of normal serum without recombinant mortalin was
subtracted from all samples in the plate. A typical calibration
curve is shown in Supporting Information Figure S1.
Statistical analysis
Statistical analysis was performed using the SPSS 15.0 soft-
ware (SPSS Inc., Chicago, IL). Patients’ survival was tested by
the Kaplan–Meier survival analysis, using the Log Rank test.
The power of the study to identify the observed difference in
mortality rate (0.18) between low- and high-mortalin groups
was 0.78. The impact of soluble mortalin and other factors
on patients’ survival was tested by the Cox proportional
hazards analysis (univariate and multivariate analyses). The
results of the Cox regression models are presented as hazard
ratios, the corresponding 95% conﬁdence intervals (CI) and
the Wald chi-square and p values of likelihood ratio tests.
Results
Concentration of mortalin in sera of patients with
colorectal cancer
Mortalin is shed in vitro from complement attacked viable
human erythroleukemia cells.14 Release of mortalin in vitro
was also demonstrated from human colon carcinoma
HCT116 cells (Supporting Information Fig. S2), mouse colo-
rectal CT26 cells, mouse lymphoma EL4 cells, mouse bladder
carcinoma MBT2 cells and human B lymphoma Raji cells
(Masarwa and Fishelson, in preparation). In order to measure
What’s new?
Mortalin is a ubiquitous mitochondrial chaperone protein that protects cells from apoptosis and is overexpressed in cancer
cells. Here, a novel ELISA developed for the detection and quantification of circulating mortalin in sera of colorectal cancer
patients is described. The assay revealed that high circulating levels of both mortalin and the closely related cytosolic protein
HSP70 are indicative of short patient survival. The results suggest that mortalin, HSP70, and TNM staging are independent
survival determinants for colorectal cancer.
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mortalin level in patients’ blood, we set to develop a sensitive
mortalin ELISA with a low background reading. Several alter-
native protocols were tested and ﬁnally the captured ELISA
described in details under Methods was found to be satisfac-
tory. This mortalin ELISA gave a reproducible and sensitive
detection of 0.25 ng of mortalin in 33 diluted human se-
rum. Each ELISA plate had wells with normal human serum
alone or human serum with increasing amounts of recombi-
nant mortalin. Normal human serum gave a low background
readout that was subtracted from all samples. The recombi-
nant mortalin samples gave a linear dose-dependent calibra-
tion curve (Supporting Information Fig. S1) that was used to
convert the optical density readout of the clinical samples
into ng mortalin.
By using this ELISA, signiﬁcant amounts of soluble mor-
talin were detected in serum samples of all colorectal cancer
patients (14–215 ng/ml). Patients were divided into two
groups, according to their serum mortalin level. The low
mortalin group (n5 88) had serum mortalin concentration
below 60 ng/ml, whereas the high mortalin group (n5 33)
had levels equal to or higher than 60 ng/ml. This concentra-
tion of mortalin was chosen based on receiver operating
characteristic (ROC) calculation to yield optimal stratiﬁcation
of patients regarding mortalin levels and survival.
Mortalin concentrations were analyzed in relation to the
tumor stage of the patients determined in earlier studies.18,19
There was no difference in the mortalin levels among the
patients with different size of tumors (TNM-T) (p5 0.151,
Kruskal–Wallis test), among patients with different extent of
lymph node involvement (TNM-N) (p5 0.346, Kruskal–
Wallis test) or between patients with or without distant
metastases (TNM-M) (p5 0.205, Mann–Whitney test). Like-
wise, there was no signiﬁcant association between mortalin
levels and different Duke’s grade categories and grade of pri-
mary tumor (both p> 0.050, data not shown). Similarly, data
were available on the serum levels of sHSP70, C-reactive pro-
tein (CRP) and C1-Inhibitor in these patients,18,19 Mortalin
concentrations did not show correlation to the sHSP70 con-
centrations (Spearman correlation coefﬁcient R5 0.051,
p5 0.580) or CRP levels (R5 0.018, p5 0.878) whereas a sig-
niﬁcant correlation (R5 0.335, p< 0.001) was found between
serum mortalin and C1-Inhibitor concentrations.
Univariate survival analysis
Kaplan–Meier survival analysis of patients with low (<60
ng/ml) vs. high (>60 ng/ml) mortalin level in serum during
a 10-year follow-up gave a Log Rank overall comparison of
p5 0.042 between the two groups, with 113 months esti-
mated median survival in the low mortalin group and 29
months median survival in the high mortalin group (Fig. 1a).
Univariate analysis by Cox regression of the variables: age
and sex of the patients, TNM-N and TNM-M stage of the
disease as well as serum mortalin and sHSP70 concentrations
are presented in Supporting Information Table S1. Only
patients without missing data were included in this analysis
(n5 99). Age was found to be a highly signiﬁcant factor with
a hazard of 1.04 per year (p5 0.002). Females had a Hazard
of 1.62 (p5 0.029) relative to males. Both TNM-N (metasta-
ses in the regional lymph node) and TNM-M (distant metas-
tases) were highly signiﬁcant predictors of mortality while
TNM-T was not (data not shown). High sHSP70 serum con-
centration (>1.65 ng/ml) was associated with mortality with
Figure 1. Survival (Kaplan-Meier) of colorectal cancer patients. (A) Patients divided according to mortalin level in their serum; high (60
ng=ml) or low (<60 ng=ml). Log Rank overall comparison showed significant equality of survival distribution (p 50.042). (B) Patients di-
vided according to their mortalin (low: <60 ng=ml, high: >60 ng=ml) and sHSP70 (low: <1.65 ng=ml, high: >1.65 ng=ml) levels. Analysis
by Cox regression HR (with 95% CI) of patients with both high mortalin and high sHSP70 vs. both low mortalin and low sHSP70 is indi-
cated. Number of patients in each category, on months: 0, 12, 24, 36, 48 and 60, is shown below the figures.
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a HR of 1.86 (p5 0.006). High mortalin (>60 ng/ml) level is
a signiﬁcant factor (p5 0.048) with a hazard ratio of 1.73. In
this analysis, patients with high and low serum mortalin lev-
els had a mean survival time of 43.19 (32.39–53.99) months
and 72.52 months (62.78–82.76), respectively (p5 0.046).
Multivariate analysis: Independent and additive
effects of risk factors
The association of the same variables with mortality of the can-
cer patients was evaluated by multivariate Cox regression anal-
ysis (Table 1). The effects of age and sex were found to be
insigniﬁcant, while the hazard of TNM-N11TNM-N2 stages
vs. TNM-N0 stage (lymph nodes involved, yes vs. no) remained
highly signiﬁcant (HR 3.34 (p5 0.001). Similarly, patients with
distant metastasis had signiﬁcantly higher risk (HR: 4.04;
p< 0.001) than those with no distant metastases. In the multi-
variable model, the hazard ratio associated with high sHSP70
was 3.508 (p< 0.001) while high mortalin concentrations
exhibited a weak but still signiﬁcant association with mortality
of patients, independently of the sHSP70 levels (Table 1).
Thereafter, we analyzed the survival of the patients strati-
ﬁed according to sHSP70 and mortalin levels (Fig. 1b). In
this type of multivariate analysis, high mortalin level with
low sHSP70 or low mortalin with high sHSP70 did not affect
the mortality of patients. In contrast, patients with concomi-
tant high mortalin and high sHSP70 concentrations had a 4.2
times higher hazard of mortality than patients with both low
sHSP70 and low mortalin levels, indicating the additive na-
ture of these two biomarkers (Fig. 1b). Median survival time
of the patients with high mortalin/high sHSP70 and low
mortalin/low sHSP70 levels were 27.5 (13.3–34.3) months
and 57.0 (31.0–81.0) months, respectively.
Finally, we examined the additive impact of serum con-
centrations of mortalin and sHSP70 on prediction of patients’
survival, as compared to the baseline model that includes
the basic demographic variables as well as the tumor stage
(Table 2). According to the results of the likelihood-ratio test
(v25 26.846. p< 0.0001), addition of the biomarkers sHSP70
and mortalin to the baseline model signiﬁcantly increased the
survival-predicting value of the model. In the subgroup of
patients with concomitantly high sHSP70 and mortlain levels,
a hazard rate of 8.176 (95% CI 3.267–20.463, p< 0.001) was
observed, indicating that the baseline model (clinical stage,
age, and sex) and the biomarkers are independent and addi-
tive predictors of mortality in colorectal cancer.
Discussion
As shown here, colorectal cancer patients have elevated mor-
talin concentrations in their blood serum. Development of a
novel and sensitive mortalin ELISA permitted us to quantify
the soluble mortalin level in blood serum of patients with
colorectal cancer. The amount of circulating soluble mortalin
was found to be variable (10–214 ng/ml) and independent on
stage of the disease.
Table 1. Multivariate analysis by Cox-regression of the association
between age and sex of the patients as well as high baseline
sHSP70 levels and high baseline mortalin levels on survival of the
patients with colorectal cancer
95.0%
confidence
interval
Variable1
Significance
(p)
Hazard
ratio Lower Upper
Age at diagnosis 0.488 1.013 0.977 1.050
Sex 0.900 0.959 0.497 1.850
TNM-N 0.001 3.337 1.661 6.704
TNM-M <0.001 4.044 2.014 8.118
Mortalin 0.044 1.976 1.019 3.831
sHSP70 <0.001 3.508 1.753 7.019
1Age (years); Sex (female/male); TMN-N (1 or 2 metastasis in the
regional lymph nodes vs. 0, yes/no); TNM-M (distant metastasis, yes/
no); sHSP70 (high: >median 1.67 ng/ml, low: <1.67 ng/ml); mortalin
(high: >median, 60 ng/ml, low: <60 ng/ml).
Table 2. Additive effect of the high mortalin and high sHSP70 levels
in serum on the age and tumor TNM-dependent mortality risk of
patients with colorectal cancer
95.0%
confidence
interval
Variable1
Significance
(p)
Hazard
ratio Lower Upper
Model 1
Age at diagnosis 0.098 1.030 0.995 1.066
Sex 0.865 0.947 0.508 1.768
TNM-N 0.003 1.853 1.234 2.784
TNM-M 0.001 3.130 1.630 6.013
Model 2
Age 0.323 1.017 0.983 1.052
Sex 0.571 1.218 0.617 2.404
TNM-N 0.003 1.879 1.244 2.840
TNM-M <0.0001 5.000 2.423 10.318
Mortalin low & sHSP70
low
– – – –-
Mortalin high & sHSP70
low
0.223 0.390 0.086 1.772
Mortalin low & sHSP70
high
0.123 1.836 0.849 3.974
Mortalin high & sHSP70
high
<0.001 8.176 3.267 20.463
Likelihood-ratio-test as compared to model 1: v2526.846.
p<0.0001
1Age (years); Sex (female/male); TMN-N (1 or 2 metastasis in the re-
gional lymph nodes vs. 0, yes/no); TNM-M (distant metastasis, yes/
no); sHSP70 (high: >median 1.67 ng/ml, low: <1.67 ng/ml); Mortalin
(high: >median, 60 ng/ml, low: <60 ng/ml). Number of patients in the
different categories (mortalin/sHsp70): low/low-46; high/ low-43; low/
high-14; high/high-18).
Analysis by model-building tool of Cox regression analysis.
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The cohort of cancer patients studied here was part of a
larger group of 175 patients with colorectal cancer studied
earlier in which the level of soluble cytosolic HSP70 was ana-
lyzed. Correlation was found between high sHSP70 and faster
disease progression in colorectal cancer.18 A follow-up study
examined in the same patients several other potential prog-
nostic bio-markers.19 High (above median) levels of CRP,
C1-INH and sHSP70 were found to be independently associ-
ated with poor patient survival. The additive effect of high
sHSP70, CRP and C1-INH levels on the survival of patients
exceeded that of high sHSP70 alone.19 Updated survival in-
formation since the previous study was available on 163
patients. Serum sample of 121 patients were tested for soluble
mortalin levels. Patients that have a higher mortalin level
(>60 ng/ml) also have a signiﬁcantly shorter median survival
time (29 months) than patients that have low mortalin level
(113 months, p5 0.042). The hazard value of high mortalin
is 1.730. Therefore, high circulating mortalin level is pro-
posed as a risk factor in colorectal carcinoma. Multivariate
analysis of survival data of 99 patients, for which age, sex,
cancer stage, soluble HSP70 and mortalin information was
available, indicated that patients with both high soluble
HSP70 and high mortalin had more than eight-times higher
risk of mortality (8.176, 3.267–20.463, p< 0.001) as com-
pared to those with low concentrations of both biomarkers.
We conclude that having concomitant high circulating
HSP70 and mortalin levels indicates bad prognosis in
patients with colorectal cancer, thus measurement of these
two biomarkers may be informative in this setting.
Immunohistochemical analysis demonstrated that mor-
talin is overexpressed in several tumor types, including colo-
rectal adenocarcinoma and hepatocellular carcinoma.9,12,13,20
Elevated mortalin in liver cancer was associated with metas-
tasis and early cancer recurrence.20 Over-expression of mor-
talin in colorectal adenocarcinomas is also correlated with
poor survival.13 Apparently, mortalin confers an advantage
to cancer growth and metastasis, but the mechanism is still
poorly characterized. In addition, mortalin promotes cell re-
sistance to complement-dependent cytotoxicity (CDC) and
may permit escape of cancer cells from antibody-based
immunotherapy.14–16 Down-regulation of mortalin, using
siRNA, antibodies or MKT-077 enhances cells sensitivity to
CDC, whereas overexpression of mortalin enhanced cell re-
sistance to CDC. As shown here, serum levels of mortalin
and HSP70 and the TNM stage are apparently independent
determinants in survival of patients with colorectal cancer.
This suggests that mortalin and HSP70 are secreted into the
blood from different tissues and/or under distinct signals.
The trigger that has induced in these patients, mortalin
release into the blood and the origin of this mortalin,
remains to be identiﬁed. Possibly, inﬂammatory or other
stress responses cause secretion of mortalin into the circula-
tion from metastatic cells and/or non-cancerous affected
tissues.
Acknowledgement
Authors thank Ilana Gelernter for her valuable assistance with the statistical
analysis of the results.
References
1. Kang PJ, Ostermann J, Shilling J, et al.
Requirement for hsp70 in the mitochondrial
matrix for translocation and folding of precursor
proteins. Nature 1990;348:137–43.
2. Bhattacharyya T, Karnezis AN, Murphy SP, et al.
Cloning and subcellular localization of human
mitochondrial hsp70. J Biol Chem 1995;270:1705–
10.
3. Wiedemann N, Frazier AE, Pfanner N. The
protein import machinery of mitochondria. J Biol
Chem 2004;279:14473–6.
4. Merrick BA, Walker VR, He C, et al. Induction
of novel Grp75 isoforms by 2-deoxyglucose in
human and murine ﬁbroblasts. Cancer Lett
1997;119:185–90.
5. Massa SM, Longo FM, Zuo J, et al. Cloning of
rat grp75, an hsp70-family member, and its
expression in normal and ischemic brain. J
Neurosci Res 1995;40:807–19.
6. Liu Y, Liu W, Song XD, et al. Effect of GRP75/
mthsp70/PBP74/mortalin overexpression on
intracellular ATP level, mitochondrial membrane
potential and ROS accumulation following
glucose deprivation in PC12 cells. Mol Cell
Biochem 2005;268:45–51.
7. Taurin S, Seyrantepe V, Orlov SN, et al.
Proteome analysis and functional expression
identify mortalin as an antiapoptotic gene
induced by elevation of [Na1]i/[K1]i ratio in
cultured vascular smooth muscle cells. Circ Res
2002;91:915–22.
8. Xu L, Voloboueva LA, Ouyang Y, et al.
Overexpression of mitochondrial Hsp70/Hsp75 in
rat brain protects mitochondria, reduces oxidative
stress, and protects from focal ischemia. J Cereb
Blood Flow Metab 2009;29:365–74.
9. Wadhwa R, Takano S, Kaur K, et al.
Upregulation of mortalin/mthsp70/Grp75
contributes to human carcinogenesis. Int J Cancer
2006;118:2973–80.
10. Wadhwa R, Takano S, Taira K, et al. Reduction
in mortalin level by its antisense expression
causes senescence-like growth arrest in human
immortalized cells. J Gene Med 2004;6:
439–44.
11. Ran Q, Wadhwa R, Kawai R, et al.
Extramitochondrial localization of mortalin/
mthsp70/PBP74/GRP75. Biochem Biophys Res
Commun 2000;275:174–9.
12. Takano S, Wadhwa R, Yoshii Y, et al. Elevated
levels of mortalin expression in human brain
tumors. Exp Cell Res 1997;237:38–45.
13. Dundas SR, Lawrie LC, Rooney PH, et al.
Mortalin is over-expressed by colorectal
adenocarcinomas and correlates with poor
survival. J Pathol 2005;205:74–81.
14. Pilzer D, Fishelson Z. Mortalin/GRP75 promotes
release of membrane vesicles from immune
attacked cells and protection from complement-
mediated lysis. Int Immunol 2005;17:
1239–48.
15. Pilzer D, Saar M, Koya K, et al. Mortalin
inhibitors sensitize K562 leukemia cells to
complement-dependent cytotoxicity.
Int J Cancer 2010;126:1428–35.
16. Pilzer D, Gasser O, Moskovich O, et al. Emission
of membrane vesicles: roles in complement
resistance, immunity and cancer. Springer Semin
Immunopathol 2005;27:375–87.
17. De Maio A. Extracellular heat shock proteins,
cellular export vesicles, and the Stress
Observation System: a form of communication
during injury, infection, and cell damage. It is
never known how far a controversial ﬁnding
will go! Dedicated to Ferruccio Ritossa.
Cell Stress Chaperones 2011;16:
235–49.
18. Kocsis J, Madaras B, Toth EK, et al. Serum level
of soluble 70-kD heat shock protein is associated
with high mortality in patients with colorectal
cancer without distant metastasis. Cell Stress
Chaperones 2010;15:143–51.
19. Kocsis J, Meszaros T, Madaras B, et al. High
levels of acute phase proteins and soluble 70 kDa
heat shock proteins are independent and additive
risk factors for mortality in colorectal cancer. Cell
Stress Chaperones 2011;16:49–55.
20. Yi X, Luk JM, Lee NP, et al. Association of
mortalin (HSPA9) with liver cancer metastasis
and prediction for early tumor recurrence. Mol
Cell Proteomics 2008;7:315–25.
Sh
or
t
R
ep
or
t
518 Mortalin and hsp70 in colorectal cancer patients
Int. J. Cancer: 133, 514–519 (2013) VC 2013 UICC
